Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Kryštufková, Olga ^a,b   Helmers, Sevim Barbasso ^c   Venalis, Paulius ^c   Malmström, Vivianne ^c   Lindroos, Eva ^c   Vencovskỳ, Jirí ^a,b   Lundberg, Ingrid E ^c  

^a INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BLOOD DENDREITIC CELL ANTIGEN 2; CD19 ANTIGEN; CELL ANTIGEN; INTERFERON; JO 1 ANTIBODY; MYXOVIRUS RESISTANCE PROTEIN; MYXOVIRUS RESISTANCE PROTEIN 1; RO52 ANTIBODY; RO60 ANTIBODY; SYNDECAN 1; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; B CELL ACTIVATING FACTOR; JO-1 ANTIBODY; RIBONUCLEOPROTEIN; SS-A ANTIGEN; TNFRSF13B PROTEIN, HUMAN; TNFRSF13C PROTEIN, HUMAN; TNFRSF17 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ADULT; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; LYMPHOCYTE COUNT; MALE; MYOSITIS; PLASMA CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; AGED; BIOPSY; BIOSYNTHESIS; CONFOCAL MICROSCOPY; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MUSCLE; PATHOLOGY;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD19; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-CELL MATURATION ANTIGEN; B-LYMPHOCYTES; BIOPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MUSCLES; MYOSITIS; RIBONUCLEOPROTEINS; SYNDECAN-1; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 84988799198     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0454-8     Document Type: Article

References (52)

1. Tansley SL, Betteridge ZE, McHugh NJ: The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013, 25:772-777.
2. Rönnelid J, Barbasso Helmers S, Storfors H, Grip K, Rönnblom L, Franck-Larsson K, Nordmark G, Lundberg IE: Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009, 9:58-61.
3. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN: The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999, 12:137-142.
4. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ: Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997, 109:32-40.
5. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
6. López De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM: Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009, 60:1160-1172.
7. Yokoyama T, Shimizu M, Ishikawa S, Ueno K, Hamaguchi Y, Takehara K, Yachie A: Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155/140 antibody-positive juvenile dermatomyositis. Mod Rheumatol 2013, 23:167-171.
8. Brunn A, Hans VJ, Vogelgesang S, Deckert M: Inflammatory myopathy with abundant macrophages and dermatomyositis: two stages of one disorder or two distinct entities? Acta Neuropathol 2009, 118:793-801.
9. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O'Connor KC, Amato AA: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65:1782-1787.
10. Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, Yao Y, Greenberg SA: Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010, 42:576-583.
11. Bradshaw EM, Orihuela A, McArdel SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O'Connor KC: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547-556.
12. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
13. Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE: Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009, 68:836-843.
14. Darce JR, Arendt BK, Wu X, Jelinek DF: Regulated expression of BAFFbinding receptors during human B cell differentiation. J Immunol 2007, 179:7276-7286.
15. Zhang X, Park CS, Yoon SO, Li L, Hsu YM, Ambrose C, Choi YS: BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005, 17:779-788.
16. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-98.
17. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H, Geha RS: TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005, 201:35-39.
18. Acosta-Rodríguez EV, Craxton A, Hendricks DW, Merino MC, Montes CL, Clark EA, Gruppi A: BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur J Immunol 2007, 37:990-1000.
19. Mackay F, Schneider P: TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008, 19:263-276.
20. Ittah M, Miceli-Richard C, Gottenberg JE, Lavie F, Lazure T, Ba N, Sellam J, Lepajolec C, Mariette X: B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 2006, 8:R51.
21. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
22. Braun D, Caramalho I, Demengeot J: IFN-α/β enhances BCR-dependent B cell responses. Int Immunol 2002, 14:411-419.
23. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Alm GV, Lundberg IE: A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007, 56:3112-3124.
24. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-α/β-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
25. Mackay F, Sierro F, Grey ST, Gordon TP: The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265.
26. Stohl W, Scholz JL, Cancro MP: Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 2011, 23:305-310.
27. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, the RIM Study Group: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013, 65:314-324.
28. Baek A, Park HJ, Na SJ, Shim DS, Moon JS, Yang Y, Choi YC: The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 2012, 249:96-100.
29. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
30. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
31. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
32. Henriksson KG: "Semi-open" muscle biopsy technique: a simple outpatient procedure. Acta Neurol Scand 1979, 59:317-323.
33. Couderc M, Gottenberg JE, Mariette X, Hachulla E, Sibilia J, Fain O, Hot A, Dougados M, Euller-Ziegler L, Bourgeois P, Larroche C, Tournadre A, Amoura Z, Mazières B, Arlet P, De Bandt M, Schaeverbeke T, Soubrier M: Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 2011, 50:2283-2289.
34. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC: Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 2011, 50:2206-2213.
35. Sem M, Molberg O, Lund MB, Gran JT: Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009, 48:968-971.
36. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP: Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007, 56:3125-3131.
37. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201:591-601.
38. Szyszko EA, Brun JG, Skarstein K, Peck AB, Jonsson R, Brokstad KA: Phenotypic diversity of peripheral blood plasma cells in primary Sjögren's syndrome. Scand J Immunol 2011, 73:18-28.
39. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH, Warnatz K: A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004, 113:161-171.
40. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V: Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
41. Brieva JA, Roldán E, De la Sen ML, Rodriguez C: Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation. Immunology 1991, 72:580-583.
42. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dörner T: Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
43. Espeli M, Bökers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011, 22:296-305.
44. Starke C, Frey S, Wellmann U, Urbonaviciute V, Herrmann M, Amann K, Schett G, Winkler T, Voll RE: High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur J Immunol 2011, 41:2107-2112.
45. Wada K, Maeda K, Tajima K, Kato T, Kobata T, Yamakawa M: Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. Histopathology 2009, 54:221-232.
46. Berggren O, Hagberg N, Weber G, Alm GV, Rönnblom L, Eloranta ML: B lymphocytes enhance interferon-α production by plasmacytoid dendritic cells. Arthritis Rheum 2012, 64:3409-3419.
47. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL: Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007, 35:17-23.
48. Cerutti A, Qiao X, He B: Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005, 83:554-562.
49. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, Noelle RJ: Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008, 180:3655-3659.
50. Król P, Kryštufková O, Polanská M, Mann H, Klein M, Beran O, Vencovskỳ J: Serum levels of interferon a do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis 2011, 70:879-880.
51. Alexaki VI, Notas G, Pelekanou V, Kampa M, Valkanou M, Theodoropoulos P, Stathopoulos EN, Tsapis A, Castanas E: Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol 2009, 183:5948-5956.
52. Chang SK, Mihalcik SA, Jelinek DF: B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 2008, 180:7394-7403.